Cardiogen

Cardiogen is usually identified as the AEDR tetrapeptide. The defensible evidence is sparse and largely preclinical. One PubMed-indexed study examined Cardiogen in organotypic myocard tissue cultures from young and old rats and reported stimulation of proliferation in myocardial explants. Another animal study investigated Cardiogen in senescent rats with transplanted M-1 sarcoma and reported tumor apoptosis and growth inhibition, which is mechanistically interesting but not direct cardiovascular evidence. A systematic review places AEDR/Cardiogen among short peptides proposed to regulate cardiovascular-system function and gene expression. No controlled human cardiovascular trials, validated dosing, regulatory labels, or robust safety studies were located.

Myocardial Tissue-Culture Signal

Cardiogen stimulated proliferative activity in organotypic myocard cultures from young and old rats, supporting cardiac-tissue research interest but not clinical benefit ^[1].

Mechanistic Classification

A systematic review lists AEDR/Cardiogen among short peptides studied for cardiovascular-system regulation and gene-expression mechanisms ^[3].

Evidence Boundary

Animal tumor-model findings are not cardiovascular outcomes and should not be translated into human cardiac or oncology claims ^[2].

No Human Cardiovascular Dataset

No human cardiovascular efficacy or phase 1 safety dataset was located for Cardiogen ^[1][3].

Preclinical Limits

Available studies leave pharmacokinetics, arrhythmia risk, hemodynamic effects, immunogenicity, carcinogenicity, and long-term toxicity unresolved ^[1][2].